Abstract
Alzheimer disease (ADa) is the most common form of senile dementia, and it is characterized pathologically by decreased brain mass. An important problem to inhibiting β-secretase, is to cross the blood-brain barrier (BBB) using drugs not derived from proteins and thus more efficient to design drugs to treat Alzheimers disease. In this sense, quantitative structure-activity relationships (QSAR) could play an important role in studying these β-secretase inhibitors. QSAR models are necessary in order to guide the β-secretase synthesis. In the present work, we firstly revised two servers like ChEMBL or PDB to obtain databases of β-secretase inhibitors. Next, we review previous works based on 2D-QSAR, 3DQSAR, CoMFA, CoMSIA and Docking techniques, which studied different compounds to find out the structural requirements. Last, we carried out new QSAR studies using Artificial Neural Network (ANN) method and the software Modes- Lab in order to understand the essential structural requirement for binding with receptor for β-secretase inhibitors.
Keywords: QSAR, CoMSIA, COMFA, docking, topological indices, β-secretase inhibitors, alzheimer's disease (AD), Romuald.Bellmann@i-med.ac.at, Lipinski Parameters,, Transport Protein, Glycerol Acetate ion, Glycerol, Protein transport hidrolase, triphloroethol, Lamarckian Genetic Algorithm
Current Bioinformatics
Title: Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Volume: 6 Issue: 1
Author(s): Francisco Prado-Prado, Manuel Escobar-Cubiella and Xerardo Garcia-Mera
Affiliation:
Keywords: QSAR, CoMSIA, COMFA, docking, topological indices, β-secretase inhibitors, alzheimer's disease (AD), Romuald.Bellmann@i-med.ac.at, Lipinski Parameters,, Transport Protein, Glycerol Acetate ion, Glycerol, Protein transport hidrolase, triphloroethol, Lamarckian Genetic Algorithm
Abstract: Alzheimer disease (ADa) is the most common form of senile dementia, and it is characterized pathologically by decreased brain mass. An important problem to inhibiting β-secretase, is to cross the blood-brain barrier (BBB) using drugs not derived from proteins and thus more efficient to design drugs to treat Alzheimers disease. In this sense, quantitative structure-activity relationships (QSAR) could play an important role in studying these β-secretase inhibitors. QSAR models are necessary in order to guide the β-secretase synthesis. In the present work, we firstly revised two servers like ChEMBL or PDB to obtain databases of β-secretase inhibitors. Next, we review previous works based on 2D-QSAR, 3DQSAR, CoMFA, CoMSIA and Docking techniques, which studied different compounds to find out the structural requirements. Last, we carried out new QSAR studies using Artificial Neural Network (ANN) method and the software Modes- Lab in order to understand the essential structural requirement for binding with receptor for β-secretase inhibitors.
Export Options
About this article
Cite this article as:
Prado-Prado Francisco, Escobar-Cubiella Manuel and Garcia-Mera Xerardo, Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors, Current Bioinformatics 2011; 6 (1) . https://dx.doi.org/10.2174/157489311795222428
DOI https://dx.doi.org/10.2174/157489311795222428 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Chemical and Biological Aspects of the Natural 1,4-Benzoquinone Embelin and its (semi-)Synthetic Derivatives
Current Medicinal Chemistry Recent Developments in Pharmacologic Prophylaxis of Atrial Fibrillation in Patients Undergoing Surgical Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Human Use of Leucoselect® Phytosome® with Special Reference to Inflammatory- Allergic Pathologies in Frail Elderly Patients
Current Pharmaceutical Design Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer’s Disease
Current Alzheimer Research Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD
Current Respiratory Medicine Reviews Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Pathology Associated Memory Deficits in Swedish Mutant Genome-Based Amyloid Precursor Protein Transgenic Mice
Current Aging Science From Nature to Market: Examples of Natural Products that Became Drugs
Recent Patents on Biotechnology Polyphenols in Disease: from Diet to Supplements
Current Pharmaceutical Biotechnology Intravenous Immunoglobulin Treatment Preserves and Protects Primary Rat Hippocampal Neurons and Primary Human Brain Cultures Against Oxidative Insults
Current Alzheimer Research Advances and Patents about Medical Surgical Operation Bone Drilling Equipment
Recent Patents on Mechanical Engineering Symmetry Plane Detection in Brain Image Analysis: A Survey
Current Medical Imaging Developing Biomarkers for Methamphetamine Addiction
Current Neuropharmacology Synthesis, Characterization and Physico-chemical Properties of New 2-(4- Arylpiperazine-1-yl)-1-(3-methylbenzofuran-2-yl)ethanoles as Potential Antihypertensive Agents
Current Organic Chemistry Possible Mechanisms of Action of NSAIDs and Related Compounds that Modulate γ - Secretase Cleavage
Current Topics in Medicinal Chemistry The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued)